Assessment of anti-thrombotic effects of conventional anti-thrombotic therapy using total thrombus-formation analysis system in transcatheter aortic valve replacement

AFTER: Assessment oF anti-Thrombotic Effects of conventional anti-thrombotic therapy using total thrombus-formation analysis system in transcatheter aortic valve Replacement - AFTER

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000041165

Enrollment

120

Registered

2020-08-01

Start date

2020-06-25

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Aortic stenosis

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who can undergo TAVI via transfemoral approach

Exclusion criteria

Exclusion criteria: Patients who met the following criteria were excluded from this study; 1) TAVI using alternative access, 2) patients who cannot take anti-thrombotic therapy prior to TAVI, 3) TAVI needed more than two valve, 4) TAVI needed emergent surgical conversion, 5) new-onset atrial fibrillation, 6) TAVI in SAV, 7) patients refused to participate this study.

Design outcomes

Primary

Measure	Time frame
Anti-thrombotic abilities	—

Secondary

Measure	Time frame
Mortality, bleeding events, thrombotic events	—

Countries

Japan

Contacts

Public ContactHirofumi Hioki

Teikyo University Department of Internal Medicine, Division of Cardiology

hioki.teikyo@gmail.com0339641211

Outcome results